MX2021004688A - Distrofinas miniaturizadas y usos de las mismas. - Google Patents

Distrofinas miniaturizadas y usos de las mismas.

Info

Publication number
MX2021004688A
MX2021004688A MX2021004688A MX2021004688A MX2021004688A MX 2021004688 A MX2021004688 A MX 2021004688A MX 2021004688 A MX2021004688 A MX 2021004688A MX 2021004688 A MX2021004688 A MX 2021004688A MX 2021004688 A MX2021004688 A MX 2021004688A
Authority
MX
Mexico
Prior art keywords
miniaturized
disclosed
methods
dystrophins
miniaturized dystrophins
Prior art date
Application number
MX2021004688A
Other languages
English (en)
Inventor
Jonathan Harry Davis
Glen Banks
Paul Charles Levesque
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2021004688A publication Critical patent/MX2021004688A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a moléculas de ácido nucleico, polipéptidos, células, vectores y composiciones farmacéuticas relacionadas con distrofina miniaturizada. También se describen métodos de producción y métodos de uso terapéutico de la distrofina miniaturizada.
MX2021004688A 2018-10-24 2019-10-24 Distrofinas miniaturizadas y usos de las mismas. MX2021004688A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862749982P 2018-10-24 2018-10-24
PCT/US2019/057855 WO2020086844A1 (en) 2018-10-24 2019-10-24 Miniaturized dystrophins and uses thereof

Publications (1)

Publication Number Publication Date
MX2021004688A true MX2021004688A (es) 2021-06-04

Family

ID=68582390

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004688A MX2021004688A (es) 2018-10-24 2019-10-24 Distrofinas miniaturizadas y usos de las mismas.

Country Status (16)

Country Link
US (1) US20210403947A1 (es)
EP (1) EP3870202A1 (es)
JP (1) JP2022505816A (es)
KR (1) KR20210082193A (es)
CN (1) CN113613668A (es)
AU (1) AU2019368307A1 (es)
BR (1) BR112021007480A2 (es)
CA (1) CA3117738A1 (es)
CL (1) CL2021000994A1 (es)
CO (1) CO2021005083A2 (es)
EA (1) EA202191123A1 (es)
IL (1) IL282547A (es)
MX (1) MX2021004688A (es)
PE (1) PE20211110A1 (es)
SG (1) SG11202104051VA (es)
WO (1) WO2020086844A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR121954A1 (es) 2020-04-29 2022-07-27 Bristol Myers Squibb Co Distrofinas miniaturizadas con dominios de fusión de espectrina y usos de las mismas
CN116234917A (zh) 2020-07-27 2023-06-06 安杰瑞姆生物科学公司 Dna分子组合物及其制备方法和使用方法
US20240003898A1 (en) * 2020-10-30 2024-01-04 Pfizer Inc. Methods for measuring dystrophin in tissue samples
EP4337267A1 (en) * 2021-05-11 2024-03-20 RegenxBio Inc. Treatment of duchenne muscular dystrophy and combinations thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ATE400656T1 (de) 2000-10-06 2008-07-15 Univ Michigan Mini-dystrophin nukleinsäure- und peptidsequenzen
CA2504593C (en) 2002-11-04 2016-08-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
JP6832280B2 (ja) * 2015-01-16 2021-02-24 ユニバーシティ オブ ワシントンＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｗａｓｈｉｎｇｔｏｎ 新規のマイクロジストロフィンおよび使用の関連する方法
CA2971303A1 (en) * 2016-06-21 2017-12-21 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use

Also Published As

Publication number Publication date
EA202191123A1 (ru) 2022-03-29
KR20210082193A (ko) 2021-07-02
AU2019368307A1 (en) 2021-06-10
EP3870202A1 (en) 2021-09-01
SG11202104051VA (en) 2021-05-28
CN113613668A (zh) 2021-11-05
WO2020086844A1 (en) 2020-04-30
JP2022505816A (ja) 2022-01-14
US20210403947A1 (en) 2021-12-30
CL2021000994A1 (es) 2021-09-20
IL282547A (en) 2021-06-30
BR112021007480A2 (pt) 2021-08-10
CO2021005083A2 (es) 2021-04-30
PE20211110A1 (es) 2021-06-17
CA3117738A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
MX2021004688A (es) Distrofinas miniaturizadas y usos de las mismas.
MX2019009839A (es) Celulas eritroides funcionalizadas.
EP4241784A3 (en) Artificial nucleic acid molecules for improved protein expression
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
ZA202002094B (en) Trispecific proteins and methods of use
SA517390590B1 (ar) Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
WO2015048333A3 (en) Nutritive polypeptides and formulations thereof, and methods of production and use thereof
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2021010668A (es) Proteinas de fusion de citoquinas.
MX2017014716A (es) Polipeptido de fusion anti-cancer.
WO2016127179A3 (en) Immunomodulatory agents
PH12019500571A1 (en) Anti-pd-1 antibodies
MX2021008318A (es) Nuevos polipeptidos de union especifica y usos de los mismos.
CA3057899A1 (en) Diaphragm-specific nucleic acid regulatory elements and methods and use thereof
EP3964575A3 (en) Alpha-amylase variants and polynucleotides encoding same
MY192824A (en) Compound targeting il-23a and tnf-alpha and uses thereof
EP4219540A3 (en) Ctla-4 variant immunomodulatory proteins and uses thereof
WO2018202921A3 (en) Nanostructured proteins and uses thereof
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
WO2016095934A3 (en) A novel genetic device to engineer cell behavior
MX2018005872A (es) Profarmacos de acido nucleico.
WO2017100313A8 (en) Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells
MY191081A (en) Compound targetting il-23a and b-cell activating factor (baff) and uses thereof